HC Wainwright set a $4.00 price objective on Capricor Therapeutics (NASDAQ:CAPR) in a report published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other equities analysts also recently commented on CAPR. Zacks Investment Research upgraded Capricor Therapeutics from a sell rating to a hold rating in a research report on Monday, January 14th. Maxim Group restated a hold rating on shares of Capricor Therapeutics in a research report on Wednesday, February 6th. Finally, ValuEngine upgraded Capricor Therapeutics from a hold rating to a buy rating in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $2.83.
Shares of Capricor Therapeutics stock traded up $0.01 during trading hours on Tuesday, hitting $0.38. The company’s stock had a trading volume of 6,240 shares, compared to its average volume of 134,150. Capricor Therapeutics has a 12-month low of $0.31 and a 12-month high of $1.58. The company has a market capitalization of $13.12 million, a price-to-earnings ratio of -0.73 and a beta of 1.45.
Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. Capricor Therapeutics had a negative return on equity of 225.30% and a negative net margin of 936.22%. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.40 million. Analysts forecast that Capricor Therapeutics will post -0.42 earnings per share for the current year.
A hedge fund recently bought a new stake in Capricor Therapeutics stock. US Bancorp DE acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 74,625 shares of the biotechnology company’s stock, valued at approximately $35,000. US Bancorp DE owned approximately 0.22% of Capricor Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 4.73% of the company’s stock.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Article: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.